You are here

Invokana

J&J looks to toss its SGLT2 hat in the ring for two types of heart failure

Endpoints

Sun, 11/14/21 - 10:47 pm

clinical trials

Bayer faces an uphill fight with finerenone

EP Vantage

Mon, 10/26/20 - 11:13 am

diabetic kidney disease

clinical trials

FDA pulls J&J's Invokana boxed warning after reviewing amputation risks—but the sales damage is done

Fierce Pharma

Thu, 08/27/20 - 10:15 pm

Janssen taps wearable tech in Invokana heart failure trial

Pharmaforum

Mon, 11/18/19 - 10:05 am

real world evidence

J&J taps kidney specialist Vifor for Invokana marketing help

Fierce Pharma

Mon, 11/4/19 - 07:16 pm

J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?

Fierce Pharma

Mon, 09/30/19 - 11:47 pm

diabetic kidney disease

type 2 diabetes

EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

Fierce Pharma

Tue, 09/17/19 - 03:41 pm

Mark Your Calendar For These September PDUFA Dates

Yahoo/Benzinga

Wed, 08/28/19 - 12:53 pm

Xeris Pharmaceuticals

Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease

Endpoints

Wed, 06/12/19 - 10:02 am

cardiovascular disease

J&J’s Invokana closes on diabetic kidney disease approval

Pharmaforum

Thu, 05/23/19 - 09:50 am

diabetic kidney disease

priority review

Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs

Fierce Pharma

Thu, 05/9/19 - 11:04 pm

Boehringer Ingelheim

Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks

Endpoints

Sun, 04/14/19 - 11:58 pm

Questions Raised About Invokana Label Expansion For CV Risk Reduction

Forbes

Thu, 11/1/18 - 11:31 am

type 2 diabetes

Johnson & Johnson bags long-awaited cardiovascular nod for diabetes drug Invokana

Fierce Pharma

Wed, 10/31/18 - 11:52 am

type 2 diabetes

J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial

Endpoints

Mon, 07/16/18 - 10:24 pm

chronic kidney disease

J&J taps German Merck to market Invokana in China

Biopharma Dive

Fri, 07/13/18 - 11:04 pm

ADA: J&J's Invokana and rivals cut heart failure hospitalizations without increasing amputation risk

Fierce Pharma

Mon, 06/25/18 - 09:12 pm

ACC: Waiting on the FDA's heart-helping verdict, J&J touts more positive CV data for Invokana

Fierce Pharma

Sun, 03/11/18 - 06:10 pm

J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits

Fierce Pharma

Fri, 11/24/17 - 09:23 am

Boehringer Ingelheim

CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana

Fierce Pharma

Wed, 08/2/17 - 11:57 am

Boehringer Ingelheim

Pages